Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 70Breast Neoplasms 52Ovarian Neoplasms 43Lung Neoplasms 24Neoplasms 21Neoplasm Metastasis 20Fallopian Tube Neoplasms 20Carcinoma, Ovarian Epithelial 18Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Stomach Neoplasms 8Recurrence 8Endometrial Neoplasms 8Adenocarcinoma of Lung 8Melanoma 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Uterine Neoplasms 4Solid Tumors 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Thoracic Neoplasms 3Testicular Neoplasms 3Solid Tumor 3Sarcoma 3

Interventions

iadademstat 1Temozolomide 1Sunitinib 1Paclitaxel 1PE regimen 1Irinotecan 1Fluorouracil 1Everolimus 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Neuroendocrine × Paclitaxel × Clear all
NCT05420636 2025-07-30

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Fox Chase Cancer Center

Phase 2 Terminated
20 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡